v3.26.1
Note 13 - Net Loss per Share - Net Loss per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Net loss $ (13,909) $ (26,908)
Less: Series B Convertible Preferred Stock dividends earned (9,719) (9,110)
Net loss attributable to Lucid Diagnostics Inc. common stockholders $ (23,628) $ (36,018)
Weighted average common shares outstanding, basic and diluted (in shares) 140,096,782 68,796,392
Net loss per share - basic and diluted (in dollars per share) [1] $ (0.17) $ (0.52)
Series B and B-1 Preferred Stock [Member]    
Less: Series B Convertible Preferred Stock dividends earned $ (9,719) $ (9,110)
[1] Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.